



BIODIEM LTD  
ABN 20 096 845 993  
Level 4,  
100 Albert Road,  
South Melbourne, Victoria, 3205  
Australia  
Phone: +613 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### Company Update and EOFY 2020 Information

#### Highlights:

- **Chinese LAIV progress**
- **Progress in Opal research study program**
- **EOFY 2020 valuation for tax purposes**

**Melbourne, 7 July 2020:** Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update.

#### **Live attenuated flu virus (LAIV) vaccine licensee progress in China**

BioDiem’s LAIV licensee in China, Changchun BCHT Biotechnology Co (BCHT), has advised that it is on track for the launch of its product “Influenza Vaccine, Live, Nasal, Freeze-dried” for the Chinese 2020-2021 ‘flu season. BCHT gained marketing approval for its seasonal influenza LAIV vaccine from the Chinese National Medical Products Administration (formerly known as the Chinese FDA). Following the launch BCHT will use its strong distributor network which covers all provinces and municipalities in mainland China, except Tibet.

China-based BCHT holds an exclusive licence from BioDiem for the influenza technology based on the live attenuated influenza virus (LAIV) vaccine technology. BCHT’s licence covers the private sector market of China for pandemic and seasonal influenza vaccines made using an egg-based production method.

BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation. In addition to annual milestone fees BioDiem will receive royalties from the sale of BCHT’s influenza vaccine product in the China private sector market.

#### **Opal Biosciences Ltd (“Opal”)**

Opal’s antimicrobial drug, BDM-I, is being developed to treat infections including those resistant to currently available antibiotics. The results of the next stage of work are expected shortly. This includes results of a mouse infection study and also completion of synthesis of new analogues of BDM-I for testing. For the analogue work, Opal has benefited under the CSIRO Kick Start program which gives financial assistance to eligible companies.

#### **EOFY Share Price information**

For EOFY 2020 valuation purposes, the last sale price of

- BioDiem ordinary shares = \$0.08 (8 cents)
- BioDiem preference shares = \$0.08 (8 cents)

For those BioDiem shareholders who also separately hold shares in Opal, the EOFY 2020 valuation of Opal Biosciences ordinary shares = \$0.25.

#### **Shareholder Information at Share Registry, Computershare.**

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre ([www.computershare.com.au](http://www.computershare.com.au)).

### **About BioDiem Ltd**

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income is from licence fees and royalties on sales.

BioDiem's technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. BioDiem has licensed the LAIV to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply and to two commercial partners, in India and China:

- Serum Institute of India's Nasovac-S™ is marketed in India; and
- Changchun BCHO Biotechnology has received Chinese National Medical Products Administration approval for marketing of its "Influenza Vaccine, Live, Nasal, Freeze-dried" vaccine in China.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit [www.biodiem.com](http://www.biodiem.com).

### **About Opal Biosciences Ltd**

Opal Biosciences is a preclinical stage Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more common difficult-to-treat infections, and few new treatments.

Opal is developing a small molecule, BDM-I, as a therapeutic to treat serious human infections including those resistant to antibiotics. BDM-I is in the preclinical stage of development and has obtained development assistance from international agencies.

For more information, please visit [www.opalbiosciences.com](http://www.opalbiosciences.com).

### **Further information**

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences